Mannose-terminated glucocerebrosidase (alglucerase; Ceredase®) was designed for enzyme replacement therapy in Gaucher disease to take advantage of mannose receptor-mediated endocytosis by macrophages. To provide a rational basis for designing enzyme replacement therapy protocols, we examined the in vitro binding, uptake, and degradation ofalglucerase by murine and human macrophages. Both were found to have -500,000 mannose-dependent receptors for alglucerase per cell with a Kd of 10-' M at 0°C. In contrast, the number of binding sites for mannose-bovine serum albumin (mannose-BSA), the classical ligand for the mannose receptor, was only 20,000 with a Kd of 10-8 M. Alglucerase was also bound in a mannose-dependent manner by cells that lack the capacity to bind mannose-BSA, such as Cos-1 cells, endothelial cells, and peripheral blood monocytes. The fact that the binding of alglucerase by macrophages was mediated principally by a receptor distinct from the classical mannose receptor that binds mannose-BSA was confirmed by differential inhibitors, viz., amethyl-glucoside, fucose, and mannose-BSA, and by its independence on Ca2+.
Introduction
Gaucher disease is an autosomal recessive disorder caused by a deficiency of glucocerebrosidase, the enzyme required for the lysosomal degradation of the sphingoglycolipid glucocerebro-side ( 1 ). In its absence the insoluble glucocerebroside accumulates in macrophages. Because reticuloendothelial cells by their very nature should take up exogenously administered material, this disorder seemed particularly well suited to enzyme replacement therapy. Although a number of attempts to treat the disorder with exogenously administered enzyme were made in the 1970s, the results were disappointing (2) (3) (4) (5) (6) . With the discovery of mannose receptors on macrophages and their role in endocytosis (7) , it was suggested (8, 9 ) that incorporating a mannose signal into native enzyme might be useful for enzyme targeting in Gaucher disease. Although -20% of the total oligosaccharides on the native glucocerebrosidase are high mannose type (10) , sequential deglycosylation to produce a mannose-terminated enzyme to improve the efficacy of targeting was proposed ( 11) . Ultimately, this modified enzyme became available commercially as a licensed treatment for Gaucher disease (alglucerase; Ceredase®). Although several groups have reported promising clinical results using alglucerase (12) (13) (14) , the optimal dose and frequency of administration of alglucerase are controversial (15) (16) (17) .
The design of optimal protocols for enzyme replacement therapy requires understanding of the kinetics of alglucerase targeting. In this report, we examine the binding, uptake, and degradation ofalglucerase by murine and human macrophages in vitro. ( 18) . 2 ml of diluted Ceredase® was applied to a column (0.7 x 2.5 cm) equilibrated with buffer A (50 mM citrate/NaOH, 50 mM NaCl, 0.5% taurocholic acid, pH 6.0). The column was washed with 15 ml ofbuffer A followed by elution with 50 ml of buffer A containing 0.2 M methyl-a-mannopyranoside. The eluate was concentrated using PM30 (Amicon, Beverly, MA) and dialyzed against PBS overnight. This alglucerase preparation was determined to be pure by use of SDS-PAGE with a specific activity of 50 U/mg protein and on SDS-PAGE a subunit molecular weight of 59,300.
Iodination ofalglucerase and mannose-BSA. 100 ,ug of protein was incubated with 0.5 mCi of Na'25I (Amersham Corp., Arlington Heights, IL) and 10 ltg of Iodo-Gen (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) immobilized in a polystyrene tube for 10 min. The reaction was terminated by gel filtration on a PD-10 column (Pharmacia LKB Biotechnology Inc.). Protein determination was performed by the Lowry et al. method (19) . Specific radioactivity was typically 2-3 X 106 cpm/jgg for alglucerase and 5-6 X 106 cpm/,gg for mannose-BSA and, on average, 94% oftotal counts were TCA precipitable.
Murine peritoneal macrophages. Peritoneal macrophages were obtained by irrigating the peritoneal cavity of 6-8-wk-old female BALB/ CBYJ mice with medium (medium 199 plus 10% FCS). Cells were washed, resuspended in the same medium, and seeded into 24-well plates (Coming Glass Inc., Coming, NY) at 5 X 105 cells per well. Adherent cell monolayers were prepared after a 4-h incubation at 370C in the presence of 5% CO2 by washing unattached cells from the plate with assay medium. Adherent cell monolayers at this stage will be referred to as murine macrophages and were used in various assays.
Human monocyte-derived macrophages. Uptake and binding assays. Assays for uptake and binding in adherent cells were done according to the method previously described with some modifications (21) . The medium was removed and cells were washed twice with HHBG (HBSS, 10 mM Hepes, 10 mM N-tris(hydroxymethyl)methyl-2-aminoethane-sulfonic acid, 0.1% glucose, and 1% BSA). Labeled alglucerase with or without mannan (3 mg/ml) in HHBG was added in a final volume of 0.4 ml. After incubation, the medium was removed and an aliquot was precipitated with 10% TCA to determine acid-soluble counts. The cell layer was washed four times with HBSS, and then solubilized in 0.5 ml of 1.0 N NaOH for determination of cell-associated radioactivity. Assays were conducted at 0°C (binding) or 37°C (uptake). Binding and uptake in the presence of mannan is designated as mannose independent. The difference between binding or uptake with or without mannan is designated as mannose dependent. Murine peritoneal macrophages were enumerated in a hemocytometer after 5 min of incubation in 0.005% Zwittergent (Calbiochem, San Diego, CA) (22) . As it is difficult to detach human monocyte-derived macrophages with intact shape in 0.005% Zwittergent, cells were dissolved in 0.1% Triton X-100 and their nuclei were enumerated. Endothelial cells were detached in trypsin-EDTA solution (Whittaker Bioproducts).
Transfection ofthe mannose receptor full-length cDNA into Cos-J cells. Cos-l cells were maintained in DME supplemented with Assay for glucocerebrosidase activity. Enzyme activity was measured using 4-methyl umbelliferyl-fl-glucoside as substrate (24) .
Results
Competition ofunlabeled with labeled alglucerase. Fig. 1 Binding and uptake of alglucerase by murine peritoneal macrophages. The time course of mannose-dependent binding at 0C showed that it reached equilibrium after 120 min (Fig.  2) . Using 180-min incubations, we examined the concentration dependence of alglucerase binding (Fig. 3 A) . Analysis of mannose-dependent binding by the Scatchard method provided an estimate of 4.5 X I05 receptors per cell with Kd = 1.2 X 10-7 M (Fig. 3 B) . Scatchard analysis of mannose-independent binding shows there are two major classes ofbinding sites, a small number of sites with high affinity (0.5 x 10 sites per cell, Kd = 9.8 X IO-O M) and a number of sites too large to measure accurately with low affinity (Fig. 3 C) . Studies in the presence ofboth mannan and galactose showed lack ofthe high affinity binding, suggesting that this binding site with high affinity might be a galactose receptor (Fig. 3 D) .
Uptake of alglucerase at 370C was approximately linear for 2 60 min (Fig. 4) Degradation ofthe internalized alglucerase in murine peritoneal macrophages. Cells were incubated with labeled alglucerase at 370C for 60 min, after which they were washed free of excess labeled alglucerase, resuspended in prewarmed medium, and further incubated at 370C. The TCA-precipitable and -soluble radioactivity in the medium and the cell-associated radioactivity were measured at intervals. Cell-associated TCA-soluble radioactivity was negligible (data not shown). Fig. 6 shows that there was a rapid decrease of cell-associated radioactivity followed by a plateau. Two thirds of the radioactivity remained after 4 h. Small but gradually increasing amounts of TCA-soluble materials were detected in the medium, indicating that proteolytic degradation ofalglucerase occurs very slowly. Corresponding to the decrease in cell-asso- =~t Time (h) Figure 6 . Fate of the internalized alglucerase in murine peritoneal macrophages. Murine peritoneal macrophages were incubated with 40 ,g/ml (6.7 x 10-7 M) of labeled alglucerase for 60 min at 370C
followed by washing with Hank's solution at 0C. Cells were incubated in fresh medium without alglucerase at 370C. At the time indicated, the medium and the first wash were combined and precipitated with 10% TCA to determine acid-soluble counts. Cell-associated radioactivity was determined as described in Methods. For one portion of the cells the medium was replaced with fresh medium at the 2-h point and further incubated at 370C. Radioactivity present in each fraction is expressed as percent of the total initial cell-associated radioactivity after incubation with labeled alglucerase. Results are the mean of duplicate assays and are representative of three independent experiments.
The Scatchard plot of mannose-dependent binding yielded a value of 6.3 X 105 receptors per cell, with a dissociation constant of 7.0 x 10-8 M (Fig. 7 B) . In contrast to murine peritoneal macrophages, mannose-independent binding sites with a high affinity constant were not observed but the number of low-affinity, mannose-independent sites were again too large to measure (Fig. 7 C) . The mannose-dependent uptake was concentration dependent and, from a double reciprocal plot, the concentration giving one-half maximal uptake was determined to be 1.1 X 10-6 M (Fig. 8) . Compared with murine peritoneal macrophages, the percentage of mannose-independent uptake in total uptake was somewhat higher in human monocyte-derived macrophages.
Degradation ofthe internalized alglucerase in human monocyte-derived macrophages. Because mannose-independent uptake is high by human monocyte-derived macrophages, we examined separately the fate of alglucerase that was taken up both in the presence and the absence of mannan. As shown in Fig. 9 , rapid release of intact labeled alglucerase into medium and concomitant decrease in cellular labeled alglucerase were observed just as in murine peritoneal macrophages. About half of the alglucerase that had been taken up in the presence of mannan remained intracellularly after 5 h.
Uptake of alglucerase by monocyte-derived macrophages from a Gaucher disease patient. Using blood from a Gaucher disease patient, we prepared monocyte-derived macrophages and examined the uptake ofunlabeled alglucerase by these cells by measuring cellular catalytic activity using 4-methyl umbelliferyl-#-glucoside as a substrate. The patient's monocyte-de- Concentration (ig/ml) Figure 9 . Fate of the internalized alglucerase in human monocyte-derived macrophages. Cells were incubated with 10 Ag/ml (1.7 X 10' M) of labeled alglucerase in the presence or absence of mannan for 60 min at 37°C followed by washing with Hanks' solution at 0°C. Cells were further incubated in fresh medium without alglucerase at 37°C. At the time indicated, medium and cells were treated as shown in Fig. 6 . Radioactivity present in each fraction is expressed as percent of the total initial cell-associated radioactivity after incubation with labeled alglucerase. Results are the mean of duplicate assays and are representative of three independent experiments. Binding and uptake ofalglucerase by Cos-l cells transfected with the mannose receptorfull-length cDNA. To determine the relative contribution of the classical mannose receptor and Ca2+ -independent receptor for binding and uptake ofalglucerase, we examined binding and uptake of alglucerase by control and mannose receptor cDNA-transfected Cos-1 cells. Cos-1 cells have been shown to lack the classical mannose receptor for mannose-BSA and gain the ability to bind this ligand after being transfected with mannose receptor cDNA (23) . We confirmed that these cells acquired the capacity to bind and take up mannose-BSA in a mannose-dependent manner (Fig. I 1) . Although there is no increase of mannose-dependent binding of alglucerase in transfected cells compared with control cells, the uptake of alglucerase by transfected cells was greater, but not significantly so.
Binding and uptake ofalglucerase by endothelial cells. As endothelial cells line blood vessels, alglucerase uptake by these cells must be considered in determining the in vivo fate of alglucerase. We therefore examined the kinetics ofbinding and uptake in umbilical cord-derived endothelial cells. Although we could not detect mannose-dependent binding of mannose-BSA (data not shown), considerable mannose-dependent binding ofalglucerase was observed (Fig. 12A) and Scatchard analysis yielded a value of 1. 1 x 106 receptors per cell, with a Kd of 2.7X 10-7M (Fig. 12B) .
The mannose-dependent uptake was concentration dependent and from a double reciprocal plot the concentration giving one-half maximal uptake was determined to be 1.1 X 10-6 M (Fig. 13 ).
Discussion
We found that murine peritoneal macrophages had 500,000 mannose-dependent receptors for alglucerase per cell with a Kd of 1.2 X 10-7 M. The number ofbinding sites is larger than has previously been described on rat alveolar macrophages by others using mannose-BSA (26) , and the affinity of receptors for alglucerase is one order of magnitude lower than that for mannose-BSA. Using mannose-BSA in our system, we ob- Cell types or activation might reflect the difference in the number of binding sites. These findings suggested that alglucerase may be bound by a receptor that is distinct from the "classical" mannose receptor that binds mannose-BSA. Since the binding is not inhibited by mannose-6-phosphate or dextran sulfate (Table II) , it is apparently not the mannose-6-phosphate re- Concentration (gog/ml) On the other hand, we found that monocytes and Cos-1 cells, which do not possess mannose receptors, bind and take up alglucerase in a mannose-dependent manner. In further investigations, we found that a-methyl-glucoside is a potent inhibitor of alglucerase binding to Cos-1 cells but has relatively little effect on the binding of mannose-BSA to macrophages. Conversely, the binding of mannose-BSA to macrophages is inhibited by fucose but the binding ofalglucerase to Cos-l cells is affected only a little by the latter sugar. In addition, alglucerase binding to Cos-1 cells is Ca2" independent whereas binding of mannose-BSA to macrophages is Ca2" dependent. To the best of our knowledge, this is the first evidence for the presence of such a Ca2 -independent mannose binding site.
Using these parameters to differentiate two binding sites, we examined whether this Ca2 -independent site might be expressed on macrophages. Binding of alglucerase to macrophages was Ca2" independent and was inhibited by a-methylglucoside or fucose in the same manner as binding of alglucerase to Cos-1 cells. Taking into account the number of binding sites of mannose receptor (2 x 104 per macrophage) and the Ca2+-independent receptor (5 X I05 per macrophage) and the fact that mannose-BSA is an effective inhibitor for only -10% of the alglucerase binding on macrophages, this type of binding site apparently accounts for the major portion ofalglucerase binding to macrophages and only a small portion of the enzyme is bound to the classical mannose receptor.
Because ofthe existence oftwo distinct binding sites, analysis of uptake of alglucerase by macrophages at 37°C is complicated. Mannose receptor cDNA-transfected Cos-1 cells serve as a good model to investigate the mechanism of alglucerase uptake. As shown in Fig. 1 1, internalization of mannose-BSA via the classical mannose receptor seems to be much more effective than that of alglucerase via the Ca2+-independent receptor. A large intracellular mannose receptor pool and its rapid recycling might be responsible for this efficient internalization of mannose-BSA (7). Although there is no difference in binding of alglucerase between control and mannose receptor cDNA-transfected Cos-1 cells, there is apparently more uptake of alglucerase by latter cells. These data suggest that at 0°C alglucerase predominantly binds to the very numerous Ca2+-independent receptor, but that at 37°C, a small number ofefficient classical mannose receptors plays a major role in the internalization of alglucerase. It may well be that only the classical mannose receptor actually delivers its ligand to the lysozyme. About one half of the alglucerase that enters macrophages merely cycles through endocytic vacuoles or even dissociates from binding sites and does not remain in the lysosome. This could be the ligand bound by the Ca2+-independent receptor.
In Table IV , we summarize the characteristics of classical mannose receptor and Ca2+-independent receptor for alglucerase expressed on macrophages.
A large number of mannose-independent binding sites were also present on macrophages. In the case of murine, but not human, cells, a few of these were high affinity sites, which appear to be galactose receptors (27), but a much larger number, 107 or greater, of low affinity sites were also found.
Our main purpose has been to evaluate the kinetics ofalglucerase binding and uptake in human macrophages, but obtaining adequate numbers of purified macrophages from humans is difficult. Recently, it was reported that under appropriate culture conditions human peripheral blood monocytes mature (25, 28, 29) . The kinetics ofthe binding and uptake of labeled alglucerase by human monocytederived macrophages was found to be quite similar to the results obtained from murine peritoneal macrophages. However, the galactose receptor detected in murine macrophages was absent from the human cells, and the proportion ofalglucerase taken up in a mannose-independent fashion was somewhat greater.
Our studies permit us to draw certain conclusions about the expected uptake of Ceredase® after infusion into human subjects. It has been reported that when alglucerase is administered in vivo at a rate of 0.13-0.45 U/kg per min, steady state levels of 1-5 X I0-8 M are achieved in the plasma (17) . Our own report of similar levels at a lower infusion rate (15) was on the basis of a specific activity of 5.0 U/mg (18), a level that was erroneously low. The levels achieved at low dose therapy are -10-9 M whereas high-dose therapy may provide levels of 10-8 M or somewhat higher. At a concentration of alglucerase of 5 x 10-8 M, achieved with high dose therapy, 80% or 16,000 of the 20,000 classical mannose receptor sites would be occupied whereas 24% or 120,000 ofthe 500,000 Ca2+-independent sites would bind alglucerase. The ratio of alglucerase bound to the classical and presumably functional sites to that bound by the inefficient Ca2+-independent sites would be 1:7.5. In contrast, the concentration of I0-9 M achieved by low dose, fractionated therapy would result in occupancy of 9% or 1,800 of the classical receptor sites and only 0.6% or 3,000 of the Ca2+-independent sites, or a ratio of 1:1.7. Thus the low concentration achieved by low dose therapy favors the classical receptor.
In our in vitro experiments at the high concentration, only -0.5% of the added alglucerase is taken up by macrophages.
At an alglucerase concentration of 10 8 M, human monocytederived macrophages take up 1.6 ng ofalglucerase per I05 cells (corresponding to 80 ,uU per 10 5 cells). As these cells normally contain 300 ,uU per 105 cells of endogenous catalytic activity, levels of only 27% of normal were achieved at this concentration. We also examined alglucerase uptake by monocyte-derived macrophages from a Gaucher patient. When incubated at a concentration of l0-7 M, which is one order of magnitude higher than the reported steady state plasma concentration when high dose therapy is given, cellular alglucerase activity of Gaucher disease patient monocyte-derived macrophages rose to < 50% of the activity found in normal macrophages. The amount of alglucerase taken up as measured by catalytic activity was slightly less than that measured by radioactivity, which may be due to either the sensitivity of the assay or the stability of the alglucerase.
Although hepatic endothelial cells are reported to possess the same mannose receptor as expressed on macrophages (30, 31 ) , umbilical cord-derived endothelial cells do not have mannose receptor (23) . However, the presence ofavid receptors for alglucerase on umbilical cord-derived endothelial cells suggests that much of the infused alglucerase may be taken up by endothelial cells. Preliminary studies of the bone marrow of patients immediately after infusion of CeredaseO is consistent with the conclusion that very little of the infused enzyme reaches macrophages. Very little of the alglucerase is found in marrow cells (our unpublished data).
We and others have clearly shown that treatment with alglucerase produces unmistakable objective improvement in patients with Gaucher disease, with marked decreases in the sizes ofthe spleen and liver in which glucocerebroside is stored (12) (13) (14) . The reason for the effectiveness of this preparation certainly is not due to efficient targeting to macrophages. It may be that the small amounts of alglucerase that do reach macrophages are sufficient to gradually reduce their burden of glucocerebroside. It is also conceivable that glucocerebroside hydrolysis occurs in unknown tissues. It is unlikely to occur in the plasma because the pH of the plasma is much higher than the pH optimum of glucocerebrosidase and because the essential co-factor, saposin, is not present (unpublished data). Our studies lead us to suggest that an efficiently targeted enzyme might have a marked therapeutic advantage over alglucerase.
